GOP Lays Groundwork To Restrict Abortion Pill With New Junk Science Report Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.

This brief notwithstanding, access to medication abortion remains at risk. The next test will be whether the Trump admin defends FDA's regulation of mifepristone on the merits - or takes other steps towards nationwide restrictions on medication abortion.

www.huffpost.com/entry/gop-la...

The Trump admin maintains the Biden admin's arguments on venue, standing, and exhaustion. DOJ also disputes the states' "birthrate" theory - that states can sue over any policy that affects their potential future birthrate. More here for Health Affairs: www.healthaffairs.org/content/fore...

The Trump admin just filed a brief that continues to defend FDA's regulation of medication abortion before a judge in Texas. As I wrote on Friday for Health Affairs, this is not too surprising, esp given the weakness of the states' arguments.

litigationtracker.law.georgetown.edu/wp-content/u...

GOP Lays Groundwork To Restrict Abortion Pill With New Junk Science Report Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.

By May 5, the Trump administration must choose whether to defend the FDA in court - or not. If not, nationwide restrictions on medication abortion (a major priority for anti-choice advocates) may soon follow.

Republican AGs in Missouri, Kansas, and Idaho are fighting to restrict mifepristone (a drug approved by FDA nearly 25 years ago that accounts for the majority of abortions in the U.S.) in every state. They want to reinstate restrictions that FDA rejected as unnecessary nearly a decade ago.

ICYMI: The Trump admin is facing a big test on medication abortion, and the stakes could not be higher. New federal restrictions from the courts or the Trump admin would dramatically reduce abortion access in states where abortion is legal and compromise reproductive health care.

Watch what happens this Monday, when the Trump DOJ has to file a brief in the Mifepristone case pending before Judge Kacsmaryk. Katie Keith has a great write-up here describing the case and setting forth the range of actions the Trump Administration might take. www.healthaffairs.org/content/fore...

We won't know until it is issued. But, in theory, it could address how Section 1557 applies to Affordable Care Act marketplace plans or potentially CMS programs. But I don't think this will be a broader rule on 1557 because the OMB entry says this rule is from CMS, not the Office for Civil Rights.

This report - published just last month by Peter Nelson, the new head of CCIIO - could offer more clues about the Biden-era policies that the Trump admin might roll back. The report touches on essential health benefits, enrollment periods, and more.

files.americanexperiment.org/wp-content/u...

Examining The Final Market Stabilization Rule: What's There, What's Not, And How Might It Work? (Updated) | Health Affairs Forefront The Trump administration has issued a final market stabilization rule. Stabilizing the individual and small group markets is an important concern, as many counties will have only one insurer next year. Does the rule do what’s needed, and what threats to market stability does it leave unaddressed?

It is anybody's guess what will be proposed. But the Trump-era rule from 2017 included policies that made it harder for consumers to enroll (shortening OEP, limiting SEPs, etc.) and deferred to states on key standards (e.g., network adequacy). More here: www.healthaffairs.org/content/fore...

Well, that didn't take long: HHS is working on a new proposed rule on the Affordable Care Act. This is currently the *only* HHS action pending at OMB. Just as it did in 2017, the Trump administration looks to be moving quickly on ACA marketplace policies.

www.reginfo.gov/public/do/eo...

Health Policy At A Crossroads: What To Watch In 2025 | Health Affairs Forefront This article does not attempt to predict the potential policies that the new administration and Congress might pursue or how they will set priorities. Instead, this article discusses the various near-...

Always read @katie-keith.bsky.social, who's back analyzing current developments in health law and policy for Health Affairs Forefront. First up: her look ahead at key events to watch for in 2025, including executive actions, litigation, and legislation. www.healthaffairs.org/content/fore...